Days after announcing a streamlined R&D strategy, Bristol-Myers Squibb said it was also implementing managerial changes, which it described in a statement as part of its pursuit of “creating a global, integrated commercial organization and expanding the scope of its finance organization.”
The changes include elevating Giovanni Caforio from the company’s president of US to the new title EVP/CFO. This puts Caforio in charge of global commercialization strategy.
The title seems very much like that of Charles Bancroft, who is EVP and CFO, but Bancroft will now oversee business development and strategy.
Now-former US oncology president Murdo Gordon is stepping into Caforio’s former role as president of US operations and Beatrice Cazala is “in the process of transitioning to a new role within the company.” FiercePharma notes Cazala’s news is an “ouch” moment, since her current title is commercial operations EVP, and this recent shakeup appears to be a sidelining of sorts.
